Tag: G-CSF market

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

G-CSF (Granulocyte Colony Stimulating Factors) Market Growth Potential: How Will Market Size Shift Through 2030?

The g-csf (granulocyte colony stimulating factors) market has shown consistent expansion in recent years. It is projected to increase from $9.48 billion in 2025 to $9.94 billion in 2026, at a compound annual growth rate (CAGR) of 4.8%. This historical growth can be attributed to factors such as the limited availability of g-csf therapies, the rising prevalence of chemotherapy-induced neutropenia, an expanding oncology patient population, regulatory approvals for first-generation g-csf products, and the adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is projected to experience substantial expansion over the upcoming years. Its valuation is set to reach $12.21 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth is driven by factors such as the introduction of innovative g-csf products, the widening presence of biosimilars in developing markets, an increase in combination therapy applications, a growing preference for pre-filled syringe formats, and enhanced investment in supportive care and programs for neutropenia management. Key trends foreseen during this period encompass an escalating demand for g-csf biosimilars, a greater uptake of pre-filled syringes and injectable options, an increase in combination treatments involving other growth factors, broader application of g-csf in oncology and blood disorder therapies, and heightened understanding of neutropenia management and supportive care.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=41480887&type=smp&name=G-CSF%20%28Granulocyte%20Colony%20Stimulating%20Factors%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

G-CSF (Granulocyte Colony Stimulating Factors) Market Growth Momentum: What Factors Are Shaping Demand?

The G-CSF (granulocyte colony stimulating factor) market is anticipated to expand due to the rising incidence of cancer. Cancer is defined as an illness marked by the unchecked proliferation and dissemination of atypical cells, capable of impairing normal bodily functions and causing mortality. This growing prevalence of cancer stems from factors like an aging demographic, shifts in lifestyle, and environmental exposures that elevate the risk of developing the disease. The G-CSF market addresses this trend by offering growth factors that encourage the production of white blood cells, thereby lowering the chances of infection and sepsis in individuals with cancer receiving chemotherapy. For example, data from October 2025, provided by the National Health Service (NHS), a UK government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, which represents an increase of 8,605 compared to 2022. Consequently, the expanding incidence of cancer is stimulating the growth within the G-CSF (granulocyte colony stimulating factor) market.

G-CSF (Granulocyte Colony Stimulating Factors) Market Breakdown By Product Type And Application

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

G-CSF (Granulocyte Colony Stimulating Factors) Market Trends Redefining Industry Growth

Companies operating within the G-CSF (granulocyte colony stimulating factor) market are concentrating on technological breakthroughs in hematopoietic treatments, including dimeric fusion protein design, to enhance neutrophil production and mitigate immunogenicity in long-acting G-CSF therapies. Dimeric fusion protein design signifies the linkage of two G-CSF molecules into a singular protein to extend its half-life and improve receptor activation without PEGylation. As an illustration, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), which is a long-acting biosimilar G-CSF intended for reducing the length of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, works by stimulating neutrophil creation in the bone marrow, thereby accelerating the recovery of neutrophil counts. Its significant attributes encompass long-acting administration, compatibility with numerous chemotherapy regimens, and a ready-to-use prefilled syringe. It is employed for the prevention of chemotherapy-induced neutropenia, mobilization of stem cells, and supportive care for immunocompromised patients, providing benefits such as fewer injections, better adherence, and superior overall patient results.

G-CSF (Granulocyte Colony Stimulating Factors) Market Company Landscape And Competitive Strategy

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

View The Full G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

https://thebusinessresearchcompany.com/report/G-CSF-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

G-CSF (Granulocyte Colony Stimulating Factors) Market Top Region By Revenue And Market Share

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

G-CSF (Granulocyte Colony Stimulating Factors) Market Expansion From $9.94 Billion In 2026 To $12.21 Billion In 2030

The granulocyte colony-stimulating factor market has experienced consistent expansion in recent times. In 2025, it was valued at $9.48 billion, and it is projected to reach $9.94 billion by 2026, reflecting a compound annual growth rate of 4.8%. This historical growth has been driven by several factors, including the restricted availability of G-CSF treatments, an increasing incidence of chemotherapy-related neutropenia, a growing number of cancer patients, regulatory endorsements for initial G-CSF therapies, and the uptake of injectable formulations.

The granulocyte colony-stimulating factors (G-CSF) market is projected to experience robust expansion over the next several years. By 2030, its value is anticipated to reach $12.21 billion, reflecting a compound annual growth rate (CAGR) of 5.3%. This forecasted growth is driven by several factors, including the introduction of innovative G-CSF products, the growing availability of biosimilars in developing markets, a heightened use of combination therapies, an increased preference for pre-filled syringe delivery systems, and amplified investment in supportive care and neutropenia management programs. Key developments shaping the market during this period involve a strong uptick in the demand for G-CSF biosimilars, greater utilization of pre-filled syringes and injectable formats, a rising trend of combining G-CSF with other growth factors, an expanded application of these products in oncology and blood disorder treatments, and an improved understanding of neutropenia management alongside supportive care practices.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

G-CSF (Granulocyte Colony Stimulating Factors) Market Demand Drivers Creating New Revenue Opportunities

The anticipated expansion of the G-CSF (granulocyte colony stimulating factor) market is being driven forward by the growing incidence of cancer. This disease is defined by the unregulated proliferation and dissemination of abnormal cells, which can impair normal bodily processes and ultimately cause death. The increasing prevalence of cancer results from factors including aging demographics, shifts in lifestyle habits, and environmental exposures that heighten cancer risk. The G-CSF market aligns with this trend by offering growth factors that boost white blood cell production, thereby lowering infection and sepsis risks in cancer patients receiving chemotherapy. As an example, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023—an average of 972 per day—which was 8,605 more than in 2022. Consequently, the rising prevalence of cancer is fueling growth in the G-CSF market.

G-CSF (Granulocyte Colony Stimulating Factors) Market Segment Landscape And Growth Potential

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

G-CSF (Granulocyte Colony Stimulating Factors) Market Trends Driving Strategic Industry Expansion

Key players in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, including the development of dimeric fusion proteins aimed at boosting neutrophil production while minimizing immunogenicity in long-acting G-CSF formulations. This approach involves merging two G-CSF molecules into a single protein structure to prolong its half-life and enhance receptor activation, bypassing the need for PEGylation. A notable example occurred in November 2023, when Evive Biotech Inc., a biopharmaceutical firm based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is designed to shorten the duration of neutropenia and febrile neutropenia in adults receiving cytotoxic chemotherapy. As a modified recombinant G-CSF, Ryzneuta promotes neutrophil generation in the bone marrow, thereby speeding up the restoration of neutrophil levels. Its standout attributes include infrequent dosing, compatibility with various chemotherapy protocols, and a convenient prefilled syringe ready for use. Indicated for preventing chemotherapy-induced neutropenia, mobilizing stem cells, and providing supportive care to immunocompromised patients, it delivers advantages such as reduced injection frequency, enhanced treatment adherence, and superior overall outcomes for individuals.

G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Access The Complete G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

G-CSF (Granulocyte Colony Stimulating Factors) Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The G-CSF (Granulocyte Colony Stimulating Factors) Market During 2026–2030?

The market size for g-csf (granulocyte colony stimulating factors) has demonstrated consistent growth in recent years. It is anticipated to expand from $9.48 billion in 2025 to $9.94 billion in 2026, registering a compound annual growth rate (CAGR) of 4.8%. Historically, this growth has been influenced by factors such as the initial limited availability of g-csf therapies, the increasing prevalence of chemotherapy-induced neutropenia, a growing oncology patient population, regulatory approvals for first-generation g-csf products, and the widespread adoption of injectable formulations.

The market size for g-csf, or granulocyte colony stimulating factors, is anticipated to show significant expansion in the coming years. It is projected to reach $12.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.3%. This expected growth during the forecast period is attributed to several factors: the introduction of novel g-csf products, the expanding presence of biosimilars in emerging markets, a greater reliance on combination therapies, the increasing demand for pre-filled syringe formulations, and a rise in investment in supportive care and neutropenia management programs. Prominent trends for this period include a growing demand for g-csf biosimilars, wider adoption of pre-filled syringes and injectable formulations, an increase in combination therapies with other growth factors, the broader application of g-csf in oncology and blood disorder treatments, and increased awareness regarding neutropenia management and supportive care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

Which Strategic Drivers Are Supporting The G-CSF (Granulocyte Colony Stimulating Factors) Market Development?

The G-CSF (granulocyte colony stimulating factor) market is anticipated to expand due to the rising occurrence of cancer. Cancer is defined by the uncontrolled multiplication and dispersion of abnormal cells, leading to disruptions in normal bodily functions and potentially death. The growing incidence of cancer is driven by elements like aging demographics, evolving lifestyles, and environmental risk factors that increase susceptibility. The G-CSF market plays a crucial role in this context by supplying growth factors that encourage white blood cell generation, thereby mitigating the danger of infection and sepsis for cancer patients undergoing chemotherapy. For example, the National Health Service (NHS), a UK government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, which represented an increase of 8,605 from 2022, as noted in October 2025. Consequently, the expanding prevalence of cancer acts as a primary catalyst for the growth of the G-CSF (granulocyte colony stimulating factor) market.

Which Segment-Based Categories Are Covered In The G-CSF (Granulocyte Colony Stimulating Factors) Market?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

Which Trends Are Contributing To Changes In The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies operating in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, specifically focusing on dimeric fusion protein design to enhance neutrophil production and reduce immunogenicity in long-acting G-CSF treatments. Dimeric fusion protein design entails linking two G-CSF molecules into a single protein, which extends its half-life and improves receptor activation without requiring PEGylation. For example, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, received U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is indicated for shortening the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, works by stimulating neutrophil production in the bone marrow, thereby accelerating the recovery of neutrophil counts. Key characteristics of Ryzneuta include long-acting dosing, compatibility with various chemotherapy regimens, and its availability in a ready-to-use prefilled syringe. It is used for the prevention of chemotherapy-induced neutropenia, stem cell mobilization, and supportive care for immunocompromised patients, providing benefits such as fewer injections, improved adherence, and better overall patient outcomes.

Which Companies Are Engaged In The G-CSF (Granulocyte Colony Stimulating Factors) Market Environment?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Access The Complete G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Region Leads The G-CSF (Granulocyte Colony Stimulating Factors) Market By Size?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access G-CSF (Granulocyte Colony Stimulating Factors) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The G-CSF (Granulocyte Colony Stimulating Factors) Market Grow Between 2026 And 2030?

The g-csf (granulocyte colony stimulating factors) market has shown steady expansion in recent years. It is projected to grow from $9.48 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.8%. Historically, this growth can be attributed to factors such as the limited availability of g-csf therapies, a rising prevalence of chemotherapy-induced neutropenia, an increasing oncology patient population, regulatory approvals for first-generation g-csf products, and the adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Several factors are expected to drive this growth during the forecast period, including the introduction of new g-csf products, the spread of biosimilars into developing markets, increased application of combination treatments, growing consumer preference for pre-filled syringe formulations, and enhanced funding for supportive care and neutropenia management initiatives. Key trends anticipated during this period encompass a surge in the need for g-csf biosimilars, wider acceptance of pre-filled syringes and injectable forms, an increase in combination therapies utilizing other growth factors, broadened application of g-csf in treating oncology and blood disorders, and heightened recognition of the importance of neutropenia management and supportive care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Major Factors Are Driving The G-CSF (Granulocyte Colony Stimulating Factors) Market Forward?

The increasing incidence of cancer is projected to stimulate the growth of the G-CSF (granulocyte colony stimulating factor) market moving forward. Cancer is defined as a disease characterized by the uncontrolled propagation and spread of abnormal cells, which can disrupt normal bodily functions and ultimately lead to death. The rise in cancer prevalence is influenced by factors such as aging populations, changes in lifestyle, and environmental exposures that elevate cancer risk. The G-CSF market supports this trend by providing growth factors that stimulate the production of white blood cells, thereby mitigating the risk of infection and sepsis in cancer patients undergoing chemotherapy. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, recorded 354,820 new cancer diagnoses in 2023, averaging 972 per day, which represents 8,605 more cases than in 2022. Therefore, the growing prevalence of cancer is a key driver for the expansion of the G-CSF (granulocyte colony stimulating factor) market.

How Is The G-CSF (Granulocyte Colony Stimulating Factors) Market Categorized Across Its Segment Groups?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

What Trends Are Influencing The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Leading companies in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, particularly through dimeric fusion protein design, to boost neutrophil production and decrease immunogenicity in extended-release G-CSF treatments. Dimeric fusion protein design involves connecting two G-CSF molecules into a singular protein to prolong its half-life and enhance receptor activation without the need for PEGylation. For instance, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is approved for reducing the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, encourages neutrophil generation in the bone marrow, thus hastening the recovery of neutrophil counts. Its significant characteristics include prolonged dosing, adaptability with various chemotherapy regimens, and availability in a convenient prefilled syringe. The product is utilized for the prevention of chemotherapy-induced neutropenia, for stem cell mobilization, and as supportive care for immunocompromised patients, providing advantages such as fewer injections, better patient adherence, and improved overall patient results.

Which Firms Are Influencing Competition In The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Get The Full G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Geographic Region Dominates The G-CSF (Granulocyte Colony Stimulating Factors) Market?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized G-CSF (Granulocyte Colony Stimulating Factors) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The G-CSF (Granulocyte Colony Stimulating Factors) Market Grow Between 2026 And 2030?

The g-csf (granulocyte colony stimulating factors) market has shown steady expansion in recent years. It is projected to grow from $9.48 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.8%. Historically, this growth can be attributed to factors such as the limited availability of g-csf therapies, a rising prevalence of chemotherapy-induced neutropenia, an increasing oncology patient population, regulatory approvals for first-generation g-csf products, and the adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Several factors are expected to drive this growth during the forecast period, including the introduction of new g-csf products, the spread of biosimilars into developing markets, increased application of combination treatments, growing consumer preference for pre-filled syringe formulations, and enhanced funding for supportive care and neutropenia management initiatives. Key trends anticipated during this period encompass a surge in the need for g-csf biosimilars, wider acceptance of pre-filled syringes and injectable forms, an increase in combination therapies utilizing other growth factors, broadened application of g-csf in treating oncology and blood disorders, and heightened recognition of the importance of neutropenia management and supportive care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Major Factors Are Driving The G-CSF (Granulocyte Colony Stimulating Factors) Market Forward?

The increasing incidence of cancer is projected to stimulate the growth of the G-CSF (granulocyte colony stimulating factor) market moving forward. Cancer is defined as a disease characterized by the uncontrolled propagation and spread of abnormal cells, which can disrupt normal bodily functions and ultimately lead to death. The rise in cancer prevalence is influenced by factors such as aging populations, changes in lifestyle, and environmental exposures that elevate cancer risk. The G-CSF market supports this trend by providing growth factors that stimulate the production of white blood cells, thereby mitigating the risk of infection and sepsis in cancer patients undergoing chemotherapy. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, recorded 354,820 new cancer diagnoses in 2023, averaging 972 per day, which represents 8,605 more cases than in 2022. Therefore, the growing prevalence of cancer is a key driver for the expansion of the G-CSF (granulocyte colony stimulating factor) market.

How Is The G-CSF (Granulocyte Colony Stimulating Factors) Market Categorized Across Its Segment Groups?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

What Trends Are Influencing The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Leading companies in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, particularly through dimeric fusion protein design, to boost neutrophil production and decrease immunogenicity in extended-release G-CSF treatments. Dimeric fusion protein design involves connecting two G-CSF molecules into a singular protein to prolong its half-life and enhance receptor activation without the need for PEGylation. For instance, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is approved for reducing the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, encourages neutrophil generation in the bone marrow, thus hastening the recovery of neutrophil counts. Its significant characteristics include prolonged dosing, adaptability with various chemotherapy regimens, and availability in a convenient prefilled syringe. The product is utilized for the prevention of chemotherapy-induced neutropenia, for stem cell mobilization, and as supportive care for immunocompromised patients, providing advantages such as fewer injections, better patient adherence, and improved overall patient results.

Which Firms Are Influencing Competition In The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Get The Full G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Geographic Region Dominates The G-CSF (Granulocyte Colony Stimulating Factors) Market?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized G-CSF (Granulocyte Colony Stimulating Factors) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The G-CSF (Granulocyte Colony Stimulating Factors) Market Grow Between 2026 And 2030?

The g-csf (granulocyte colony stimulating factors) market has shown steady expansion in recent years. It is projected to grow from $9.48 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.8%. Historically, this growth can be attributed to factors such as the limited availability of g-csf therapies, a rising prevalence of chemotherapy-induced neutropenia, an increasing oncology patient population, regulatory approvals for first-generation g-csf products, and the adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Several factors are expected to drive this growth during the forecast period, including the introduction of new g-csf products, the spread of biosimilars into developing markets, increased application of combination treatments, growing consumer preference for pre-filled syringe formulations, and enhanced funding for supportive care and neutropenia management initiatives. Key trends anticipated during this period encompass a surge in the need for g-csf biosimilars, wider acceptance of pre-filled syringes and injectable forms, an increase in combination therapies utilizing other growth factors, broadened application of g-csf in treating oncology and blood disorders, and heightened recognition of the importance of neutropenia management and supportive care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Major Factors Are Driving The G-CSF (Granulocyte Colony Stimulating Factors) Market Forward?

The increasing incidence of cancer is projected to stimulate the growth of the G-CSF (granulocyte colony stimulating factor) market moving forward. Cancer is defined as a disease characterized by the uncontrolled propagation and spread of abnormal cells, which can disrupt normal bodily functions and ultimately lead to death. The rise in cancer prevalence is influenced by factors such as aging populations, changes in lifestyle, and environmental exposures that elevate cancer risk. The G-CSF market supports this trend by providing growth factors that stimulate the production of white blood cells, thereby mitigating the risk of infection and sepsis in cancer patients undergoing chemotherapy. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, recorded 354,820 new cancer diagnoses in 2023, averaging 972 per day, which represents 8,605 more cases than in 2022. Therefore, the growing prevalence of cancer is a key driver for the expansion of the G-CSF (granulocyte colony stimulating factor) market.

How Is The G-CSF (Granulocyte Colony Stimulating Factors) Market Categorized Across Its Segment Groups?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

What Trends Are Influencing The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Leading companies in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, particularly through dimeric fusion protein design, to boost neutrophil production and decrease immunogenicity in extended-release G-CSF treatments. Dimeric fusion protein design involves connecting two G-CSF molecules into a singular protein to prolong its half-life and enhance receptor activation without the need for PEGylation. For instance, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is approved for reducing the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, encourages neutrophil generation in the bone marrow, thus hastening the recovery of neutrophil counts. Its significant characteristics include prolonged dosing, adaptability with various chemotherapy regimens, and availability in a convenient prefilled syringe. The product is utilized for the prevention of chemotherapy-induced neutropenia, for stem cell mobilization, and as supportive care for immunocompromised patients, providing advantages such as fewer injections, better patient adherence, and improved overall patient results.

Which Firms Are Influencing Competition In The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Get The Full G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Geographic Region Dominates The G-CSF (Granulocyte Colony Stimulating Factors) Market?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized G-CSF (Granulocyte Colony Stimulating Factors) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The G-CSF (Granulocyte Colony Stimulating Factors) Market Over The 2026–2030 Period?

The g-csf (granulocyte colony stimulating factors) market has experienced consistent growth in recent years. Its expansion is projected from $9.48 billion in 2025 to reach $9.94 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 4.8%. Historically, this growth was driven by factors such as the restricted accessibility of g-csf therapies, the increasing occurrence of chemotherapy-induced neutropenia, a growing population of oncology patients, the granting of regulatory approvals for initial g-csf products, and the widespread adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is anticipated to experience substantial expansion over the upcoming years, projected to reach $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This projected growth is driven by several factors, including the introduction of new g-csf products, the wider availability of biosimilars in developing regions, increased application of combination therapies, a surge in demand for pre-filled syringe formats, and heightened investment in supportive care as well as neutropenia management initiatives. Key trends anticipated during this period encompass a growing preference for g-csf biosimilars, a greater uptake of pre-filled syringes and injectable forms, an increase in combination treatments incorporating other growth factors, broader application of g-csf in oncology and blood disorder therapies, and enhanced recognition of neutropenia management and supportive care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Drivers Are Expected To Influence The G-CSF (Granulocyte Colony Stimulating Factors) Market During The Forecast Period?

The G-CSF (granulocyte colony stimulating factor) market is projected to expand due to the escalating incidence of cancer. Cancer, a serious illness defined by the unchecked growth and proliferation of abnormal cells that can impair bodily functions and result in death, is becoming more widespread. This rise in cancer cases is influenced by factors such as aging populations, changes in lifestyle, and environmental exposures that heighten cancer risk. The G-CSF market addresses this trend by providing essential growth factors that stimulate the production of white blood cells, thereby mitigating the risk of infection and sepsis in cancer patients undergoing chemotherapy. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, documented 354,820 new cancer diagnoses in 2023, which equates to an average of 972 per day and represents an increase of 8,605 compared to 2022. Thus, the increasing prevalence of cancer is a primary driver for the growth of the G-CSF (granulocyte colony stimulating factor) market.

How Is The G-CSF (Granulocyte Colony Stimulating Factors) Market Segmented Across Key Categories?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

Which Upcoming Trends Are Expected To Influence The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies in the G-CSF (granulocyte colony stimulating factor) market are concentrating on technological advancements within hematopoietic therapies, including the design of dimeric fusion proteins to increase neutrophil production and reduce immunogenicity in long-acting G-CSF treatments. Dimeric fusion protein design involves linking two G-CSF molecules into a single protein to extend its half-life and enhance receptor activation without requiring PEGylation. For instance, in November 2023, Evive Biotech Inc., a Singapore-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), a long-acting biosimilar G-CSF aimed at shortening the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, stimulates neutrophil production in the bone marrow, thereby accelerating the recovery of neutrophil counts. Its key characteristics include long-acting administration, compatibility with multiple chemotherapy regimens, and availability in a ready-to-use prefilled syringe. It is utilized for the prophylaxis of chemotherapy-induced neutropenia, stem cell mobilization, and supportive care in immunocompromised patients, providing benefits such as fewer injections, improved adherence, and better overall patient outcomes.

Who Are The Dominant Players Shaping The G-CSF (Granulocyte Colony Stimulating Factors) Market Landscape?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Read the full g-csf (granulocyte colony stimulating factors) market report here:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Region Is Forecast To Lead The G-CSF (Granulocyte Colony Stimulating Factors) Market In Terms Of Market Size?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored G-CSF (Granulocyte Colony Stimulating Factors) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3466&type=smp

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the g-csf (granulocyte colony stimulating factors) market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the G-CSF (Granulocyte Colony Stimulating Factors) Market expected to reach by 2030?

The g-csf (granulocyte colony stimulating factors) market has shown consistent expansion in recent years. It is anticipated to increase from $9.48 billion in 2025 to $9.94 billion in 2026, at a compound annual growth rate (CAGR) of 4.8%. The historical growth can be attributed to several factors including the restricted access to g-csf therapies, the rising occurrence of chemotherapy-induced neutropenia, an expanding population of oncology patients, regulatory approvals granted for initial g-csf products, and the widespread adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is projected to experience robust expansion over the coming years. This market is anticipated to reach $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this anticipated growth include the introduction of new g-csf products, the spread of biosimilars into developing regions, a rise in the application of combination therapies, escalating demand for pre-filled syringe formats, and increased spending on supportive care and initiatives for neutropenia management. Key trends expected during this period involve an escalating preference for g-csf biosimilars, greater acceptance of pre-filled syringes and injectable formats, an increase in combination therapies incorporating other growth factors, wider application of g-csf in cancer and blood disorder treatments, and enhanced understanding of neutropenia management and supportive care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Drivers Are Driving Adoption Within The G-CSF (Granulocyte Colony Stimulating Factors) Market?

The growing incidence of cancer is projected to boost the G-CSF (granulocyte colony stimulating factor) market in the future. Cancer is a condition marked by the uncontrolled multiplication and spread of abnormal cells, which can impair standard bodily functions and lead to death. The increase in cancer prevalence is driven by factors such as aging populations, changes in lifestyle, and environmental exposures that raise cancer risk. The G-CSF market addresses this by offering growth factors that stimulate the production of white blood cells, thereby mitigating the chance of infection and sepsis in cancer patients receiving chemotherapy. For instance, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which was 8,605 more than in 2022, as reported in October 2025. Hence, the rising occurrence of cancer is a key driver for the growth of the G-CSF (granulocyte colony stimulating factor) market.

What Segments Are Included Within The G-CSF (Granulocyte Colony Stimulating Factors) Market?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

Which Trends Are Guiding The Evolution Of The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies engaged in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, particularly through dimeric fusion protein design to improve neutrophil production and minimize immunogenicity in long-acting G-CSF treatments. Dimeric fusion protein design entails linking two G-CSF molecules into a unified protein to prolong its half-life and enhance receptor activation without the need for PEGylation. For instance, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, obtained U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), a long-acting biosimilar G-CSF developed to shorten the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, works by stimulating neutrophil generation in the bone marrow, thereby accelerating the recovery of neutrophil counts. Its notable features include extended dosing intervals, compatibility with diverse chemotherapy regimens, and a convenient prefilled syringe ready for use. It is prescribed for the prophylaxis of chemotherapy-induced neutropenia, stem cell mobilization, and supportive care for immunocompromised patients, offering benefits like fewer injections, enhanced adherence, and better overall patient outcomes.

Who Are The Top-Performing Companies In The G-CSF (Granulocyte Colony Stimulating Factors) Market In Recent Years?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Region Currently Holds The Largest Share Of The G-CSF (Granulocyte Colony Stimulating Factors) Market?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized G-CSF (Granulocyte Colony Stimulating Factors) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3466&type=smp

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model